Gut organoids for COVID-19 drug screening
2021
Boston University, Boston, USA(1)
Boston University School of Medicine, Boston, USA(2)
Boston University School of Medicine, Boston, USA(2)
Researchers have generated human induced pluripotent stem cells (iPSC)-derived intestinal organoids or three-dimensional (3D) models that can be infected with SARS-CoV-2. Testing how SARS-CoV-2 specifically affects the gut can potentially serve to test novel therapeutics for COVID-19. Using iPSCs, the researchers differentiated the cells into colonic and small intestine 3D organoids. The organoids were then infected with SARS-CoV-2 to analyse the effect of infection on the cells by staining against markers, by electron microscopy and by RNA sequencing. The findings suggest that different epithelial tissues (such as the lung and the gut) react in a similar manner to SARS-CoV-2 infection and therefore can help identify common mechanisms of disease that can be targeted by drugs.
Human pluripotent stem cell-derived intestinal organoids model SARS-CoV-2 infection revealing a common epithelial inflammatory response
Elke Mühlberger(1), Gustavo Mostoslavsky(2)
Added on: 06-21-2021
[1] https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(21)00099-0[2] https://www.drugtargetreview.com/news/89042/stem-cell-derived-organoids-developed-to-test-sars-cov-2-drugs-on-gut/?utm_source=Email+marketing&utm_medium=email&utm_campaign=DTR+-+Industry+Insight+-+Mol+Dev+-+Organoid+-+07.05.21&utm_term=Are+you+aware+of+the+latest+industry+updates+on+organoids%3f&utm_content=https%3a%2f%2femails.drugtargetreview.com%2frussellpublishinglz%2f&gator_td=uOX%2bhTTMM2WCbR7i2fgoRI94dnk06Cr6V1jh7Y77E0u9tlQ7GQ7R9%2f2uXmEOpnKsVDOB5O7mSa5nWIlGwhGJC15VqnrcFaM5K82nDxmIDQgbPtsj0AEli6IpplTIe%2f7vde%2bZ0vbQTmS5QO05hyxVwstuDjfkYUVR08A2V1yo0kpO8aE5H5l0uMI8nQZmlNnXAvTL7W%2f0dNocA0%2fpZMcDNLJbbNMiQax4miiMTd%2b6hfxlFZvq1ya2%2bBzB%2f4TzzOji
